Administration of recombinant human erythropoietin (rHuEPO) has been effective in reducing the need for red blood cell transfusions in preterm infants. [1] [2] [3] [4] No significant adverse effects of rHuEPO have been identified. Recently, erythropoietin (EPO) and EPO receptors (EPO-R) were found in the central nervous system of first and second trimester human fetuses. 5, 6 Juul et al. found EPO in the cerebrospinal fluid (CSF) of normal preterm and term infants and questioned whether rHuEPO crosses the blood-brain barrier and might affect the developing central nervous system of premature infants. 7 No studies have investigated the long-term neurodevelopmental effects of rHuEPO administration to preterm infants. We report the neurodevelopmental outcomes of infants who were in controlled trials of rHuEPO.
METHODS
A total of 50 preterm infants were enrolled in one of three randomized, double-blind, placebo-controlled clinical trials of rHuEPO as a treatment for anemia of prematurity. 4, 8, 9 Two pilot studies (n ϭ 28) and one multicenter trial (n ϭ 22) were conducted at the University of California, San Francisco between 1988 and 1993.
Entry criteria included birth weight of Յ1250 gm and a gestational age at birth of Յ33 weeks for the two pilot studies and Ͻ31 weeks for the multicenter trial. Infants with grade III or IV intracranial hemorrhage, periventricular leukomalacia, or major congenital anomalies were excluded.
Infants received either rHuEPO (Amgen, Thousand Oaks, CA) or an equal volume of placebo. The 20 infants enrolled in the first pilot study received twice weekly intravenous injections of 100 U/kg of rHuEPO or placebo. The eight infants in the second pilot study received the rHuEPO or placebo subcutaneously, beginning at 100 U/kg per day five times per week. In four control and three treated infants, the dose was doubled to 200 U/kg per day. A total of 22 infants enrolled at this center in the multicenter trial received rHuEPO or placebo subcutaneously at 100 U/kg per day 5 days a week. All infants received study medication for 6 weeks maximum.
At discharge, infants were enrolled in the neonatal follow-up program, where they were assessed according to a protocol for very low birth weight infants. They were serially assessed by the same neonatologist (R. E. P.) with training in developmental and behavioral pediatrics. All formal developmental testing was administered by the same psychologist (C. H. L.). Assessors were blinded to the infants' rHuEPO treatment status. Neurologic, neurosensory, and cognitive outcomes were considered as follows:
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cant abnormalities in muscle strength, tone, reflexes, or movement patterns causing functional impairment. Infants with abnormalities in tone, strength, or reflexes who did not present with a clear diagnosis after 1 year were classified as "suspect."
Neurosensory Outcome
Bilateral blindness or hearing deficits requiring hearing aids or other communication aids were classified as abnormal neurosensory outcomes.
Cognitive Outcome
The Bayley Scales of Infant Development were administered at 12 and 18 months, the Stanford Binet Intelligence Scale was administered at 2.5 to 4 years, the McCarthy Scales of Children's Abilities were administered at age 4 to 6, and the Wechsler Intelligence Scale for Children (revised) was administered at age 7 and older. Age was adjusted for prematurity to 3 years. Developmental and cognitive scores that were between 1 and 2 SD below the mean were considered borderline; scores that were Ͼ2 SD below the mean were considered deficient.
RESULTS
We obtained follow-up data on 40 of the 50 infants. Four infants died (two in each group). One rHuEPO-treated infant died of necrotizing enterocolitis before discharge, and the other died of biliary atresia after discharge. The two control infants died of sudden infant death syndrome with diagnosis confirmed at autopsy. Two control children with subsequent leukemia and traumatic head injury, respectively, were not included in follow-up. Four infants, one control and three treated, were lost to follow-up. A total of 38 children were assessed in the follow-up program; in addition, Bayley assessments were obtained from a community agency for two children. Seven children missed their infant examinations but were seen later: Four were assessed at the 2.5 year examination and three were seen only once, at age 8 years. We report results on the subset of 33 infants who completed their Bayley examinations and the overall results for the total group of 40. Table 1 shows the characteristics of the followed infants. Bayley examinations of 33 treated and untreated infants, as well as their neurologic outcomes, were compared at a mean adjusted age of 17 months. There were no significant neurosensory deficits (blindness and/or deafness). Infants in both groups obtained similar Mental Development Index scores (control ϭ 94.6 Ϯ 18.7, rHuEPOtreated ϭ 95.4 Ϯ 9.9). The test scores in both groups had a normal distribution; the difference in mean test scores was not significant (t-test for equality of means with unequal variance: t ϭ 0.15, df ϭ 26.71, p ϭ 0.878). Table 2 shows the outcome for the 40 followed infants, using the last test score and the last neurologic examination. The neurologic outcome was similar to that of the 33 infants seen at 17 months. All children in the rHuEPO-treated group were normal. A total of 18 of 20 children in the control group were neurologically normal; one child with a neonatal history of postmeningitis abscess had spastic diplegia, and one child with persistent low tone was classified as suspect.
Of the rHuEPO-treated children, 75% were in a normal range for cognitive development, compared with 65% in the control group. Two infants (one control infant and one treated infant, had declining head growth over the first year of life) eventually falling more than 2 SD below the mean.
DISCUSSION
Although EPO is a naturally occurring hormone in humans, there may be potential adverse effects in the newborn related to exogenous administration during a natural period of low hormone production. The clarification of ideal rHuEPO dosing regimens is still under inves- 2 (10) 0 (0) tigation, and various doses have been used. Reviews of randomized, placebo-controlled trials of rHuEPO treatment for anemia of prematurity report efficacy, without major side effects, at doses ranging from 500 to 1400 U/kg per week. 11, 12 Three large, randomized, placebocontrolled trials reported efficacy at doses of 500 to 750 U/kg per week.
1,2,4 Although extremely low birth weight infants have received doses of 1400 to 1500 U/kg per week without evidence of increased adverse events, 13, 14 rHuEPO dosing at 750 mg/kg per week may be as effective as 1500 mg/kg per week in reducing the need for transfusions.
14 Of the 20 infants in our sample who were randomized to treatment groups, eight infants received subtherapeutic rHuEPO doses equaling 200 mg/kg per week. The remaining 12 treated infants received doses between 500 and 1000 mg/kg per week, which are within the range of commonly used doses.
EPO and EPO-R have been identified on nonerythroid cell lines, and important nonerythropoietic functions for this cytokine growth hormone have been proposed. In vitro human and animal research has demonstrated the functional presence of EPO and EPO-R on endothelial cells, [15] [16] [17] placental cells, 18 cardiomyocytes, 19 and in the central nervous system. 6,7,20 -26 The presence of EPO and EPO-R in neural cell lines of postimplantation mouse embryos suggests a role in embryogenesis and neurogenesis as well as in hematopoiesis. 26 EPO influences the differentiation of megakaryocytes 27 and enhances Ig production on human B lymphocytes. 28 EPO-R have also been identified on human and rodent umbilical vein and brain capillary endothelial cells, where in vitro studies on rats suggest that EPO may play an important role in angiogenesis 15, 16, 29, 30 and act as a vascular competence factor. 17 Angiogenic effects of rHuEPO have also been demonstrated on rat cardiomyocytes 19 and aortic tissue. 30 EPO and other hematopoietic cytokines may regulate the differentiation of neurons in the brain, 31 and a neurotrophic role of EPO has been postulated. 21, 23, 26, [32] [33] [34] EPO-R have been identified in the hippocampus, amygdala, and temporal cortex of the human brain, where endogenous EPO production by astrocytes is induced in an oxygen-dependent manner and may have a neuroprotective function. 20 -24,32 Recent work suggests that EPO may play an important role in enhancing neuronal cell survival under sublethal hypoxicischemic insult by mediating cellular CA 2ϩ influx, thus counteracting glutamate toxicity, 23, 25 suppressing the nitric oxide-induced formation of free radicals, antagonizing free radical toxicity, 33 and preventing cell death by inhibiting apoptosis. 6 EPO and EPO-R have been identified on the spinal cords of human fetuses 5 and in the CSF of preterm and term neonates in which therapy with rHuEPO had no effect on the CSF concentration of EPO. 7 A study of adults with traumatic brain injury revealed no correlation between serum and CSF EPO concentrations but described a positive correlation between CSF EPO and the degree of blood-brain barrier dysfunction, suggesting that EPO does not cross an intact bloodbrain barrier. 22 More recently, Juul et al. 6 examined human fetal spinal cords and brains and reported expression of EPO-R on neurons, glial cells, astrocytes, and choroid plexus. Fetal cell line cultures of glial and mature neurons, exposed to hypoxic conditions, were protected from apoptosis after the introduction of rHuEPO. The presence of EPO and EPO-R in the brain suggests that the developing brain might be sensitive to exogenous administration.
The infants in this study were at moderately high risk for late handicaps. [35] [36] [37] [38] These findings are somewhat reassuring in that we did not see differences in neurologic or cognitive outcome related to rHuEPO treatment. However, the size of the sample was not large enough to detect with certainty an adverse effect that is rare. Our study sample was small, which limits the power of the study to find differences between groups. A sample size of 616 infants would have been required to achieve 80% power with a 5% two-tailed Student's t-test and critical effect size of 0.10.
Although in vitro research has shown neurotrophic and neuroprotective effects of endogenous and recombinant EPO, these effects have not been demonstrated in vivo in the human central nervous system.
Other physiological functions of EPO and EPO-R may be as yet unidentified. The role of EPO in the nervous system of neonates, the nonerythropoietic functions of EPO, the effects of rHuEPO on other organ systems, the identification of infants most likely to benefit from rHuEPO therapy for anemia of prematurity, and optimal dosing regimens need further elucidation. Additional studies of long-term outcome with a larger sample size are needed to investigate potential neurodevelopmental effects and to clearly describe side effects, especially those that are rare.
